Anifrolumab, a relatively new monoclonal protein, is generating considerable excitement within the healthcare community as a possible option for various autoimmune ailments. This distinctive medication targets the https://opensocialfactory.com/story25891973/anifrolumab-a-new-therapy-for-immune-mediated-conditions